Not exact matches
Study authors intend to perform additional research in the
future to follow up on their estimate of how well the current
vaccines protect against HPV - associated cancers.
The results from the
study could be used to help public health officials to plan a more effective response to
future pandemics, such as rolling out
vaccines at a much earlier time and targeting specific types of
vaccines at different age groups.
«If this research is borne out in
future studies, we could be less than a decade away from a safe and effective live - attenuated
vaccine for RSV.»
The new finding will help researchers formulate better
vaccines for
future flu seasons, the
study's authors conclude.
«In the
future, [the findings] could apply to
vaccines that we hope will be developed against generally lethal viruses (e.g. HIV, Ebola), encouraging scientists to strive towards «perfect
vaccines» for them,» Michael Skinner, a virologist from Imperial College London who wasn't part of the
study, told the Science Media Centre.
«It allows us in
future studies to increase the dose and alter the schedule of the
vaccine to further optimise it.
«Now that we know that [the difference] exists, it contributes to our understanding of why the
vaccine is not effective in all cases and informs
future vaccine development efforts,» said Dr. Dan Neafsey, associate director of the Genomic Center for Infectious Diseases at the Broad and co-first author of the
study.
NJTV - New Pancreatic
Study May Offer Hope for the
Future - November 17, 2011 CINJ Deputy Director Dr. Edmund Lattime and Co-Director of CINJ's Gastrointestinal - Hepatobiliary Oncology Program Dr. Elizabeth Poplin discuss early results to a unique clinical trial that uses
vaccine therapy to target pancreatic cancer.
The finding «can color how we approach
future vaccine discovery and development,» said Broad senior associate member Dr. Dyann Wirth, a top malaria researcher at Harvard who led the
study along with Fred Hutch biostatistician Dr. Peter Gilbert.
Immune responses of patients could point way forward for
future vaccines.In the latest
study, researchers involved with the trial at Mahidol University in Bangkok and the U.S. Military HIV Research Program in Washington DC assembled a team to scour the blood of trial participants for immune indicators that differed between 41 people who received the
vaccine and contracted HIV and 205 participants who did not become infected.
Study results, presented at the 2009 AIDS
Vaccine Conference, suggest that MVA - CMDR is an ideal candidate for
future prime - boost vaccination strategies.
In the
future spread her
vaccines out by more than 2 weeks - there are no great
studies on this but at a recent conference, a veterinary immunologist recommended spreading them out by really as many weeks as you can, but a minimum of 2 weeks.